Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
PK and Safety of Prusogliptin (DBPR108) in Subjects with Renal Impairment
NCT04859439Phase 1Completed
- Sponsor
- CSPC ZhongQi Pharmaceutical Technology
- Start
- Jun 2021
- Primary completion
- Nov 2021
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 1, open-label trial of prusogliptin in type 2 diabetes mellitus (T2DM) (5 arms), sponsored by CSPC ZhongQi Pharmaceutical Technology. Primary endpoints: Pharmacokinetic parameters of DBPR108 in plasma at 48 hours and Pharmacokinetic parameters of DBPR108 in urine at 48 hours. Started Jun 2021; status: completed.
02
Drugs
prusogliptin
03
Conditions
type 2 diabetes mellitus (T2DM)
Beyond the preview
Go deeper on NCT04859439.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT04859439.